BGI Genomics Co Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BGI Genomics Co Ltd.
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims.
BGI, and its subsidiary MGI, can’t sell the infringing products in the US until after Illumina’s patents expire.
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- BGI Europe A/S
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.